Daiichi Sankyo poised to add another ADC blockbuster with datopotamab deruxtecan for non-squamous NSCLC: GlobalData
Express Pharma
FEBRUARY 21, 2024
billion by 2029. “ There are multiple Phase III studies for the ADC in frontline NSCLC in combination with immune checkpoint inhibitors such as Merck’s Keytruda (pembrolizumab) or AstraZeneca’s Imfinzi (durvalumab). billion in 2023, and GlobalData projects it to surpass $14 billion by 2029.
111 
Let's personalize your content